PHI had a successful Holomonitor User Meeting where we discussed how to use HoloMonitor with focus on cancer research. The presentations showed new methods within cancer research and cell biology.
PHI’s Industrial Doctoral Student Louise Stenbaeck received a prize from Danish Cancer Society for her poster “Holographic microscopy: Macrophage-uptake of SA-MIPs”. Louise’s poster showed something new within cancer research on cell level. Her research within cell proliferation shows that morphological parameters and treatment with the plastic nanoparticles MIP:s (molecularly imprinted polymers) increased the values for cell
Cancer kills millions of people every year and is one of humanity’s greatest health challenges. In recent years, immune cells were shown to play critical roles in tumor growth and metastatic progression. The environment where tumor cells live consists of a wide range of cell types, among them immune cells. Even though the power is
The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit Interim Report 1 for the fiscal year 2018/19.
“In the near future”, Zahra El-Schich says, “you could have a HoloMonitor in every clinic. You could also customize cancer treatment for every patient by just using a simple tumor test.” Find out how.
Aktieägarna i Phase Holographic Imaging PHI AB (publ), 556542-7811, kallas härmed till årsstämma onsdagen den 26 september 2018 kl. 17.00 i bolagets lokaler, Scheelevägen 22 i Lund.
PHI’s CEO and founder Peter Egelberg comments the latest research results by the scientists at the PHI/UCSF Holographic Imaging Cytometry Center of Excellence.
Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.
Using nanoparticles and HoloMonitor technology Prof. Anette Gjörloff Wingren and her team aim to develop an early screening method that detects cancer by a simple blood test.
In this first version of App Suite three common analyzes are included: cell proliferation, cell motility, and cell quality control. App Suite will be rapidly expanded with additional applications. HoloMonitor® App Suite 2.0 is scheduled to be released to customers in Q4 2018.